DailyDoctor Archive Specialties Get app
Back to the 5 September 2026 edition

Clinical update · 03 of 05

Continuous glucose monitoring improved outcomes in gestational diabetes

Continuous glucose monitoring in gestational diabetes improved glycaemic control modestly and was associated with 8-35% fewer adverse maternal and neonatal outcomes, apparently by prompting earlier escalation of treatment.

This meta-analysis pooled 21 studies and 5,650 pregnant women, comparing continuous glucose monitoring with self-monitored blood glucose in pregnancies complicated by gestational diabetes, with low-to-moderate risk of bias.

Glycaemic measures favoured continuous monitoring across the board: mean glucose lower by 0.24 mmol/L (95% CI -0.41 to -0.06), coefficient of variation lower by 0.78%, mean amplitude of glycaemic excursions lower by 0.22 mmol/L, and time above 7.8 mmol/L reduced by 2.19 percentage points. Clinical outcomes followed, with 8-35% reductions in caesarean delivery, macrosomia, neonatal hypoglycaemia and hyperbilirubinaemia. Medication use rose by 21%.

That last figure is worth reading as a mechanism rather than a harm. Continuous monitoring finds excursions that intermittent testing misses, which prompts earlier escalation to metformin or insulin, which is plausibly how the neonatal outcomes improved. The glycaemic differences themselves are small in absolute terms — 0.24 mmol/L is not much — so the benefit likely comes from better-targeted treatment rather than from the numbers alone. The review mixes randomised and observational studies, so the outcome estimates should be treated as encouraging rather than definitive, and cost remains the limiting factor in most settings.

  • Mean glucose 0.24 mmol/L lower; time above range down 2.19 points
  • 8-35% reductions in caesarean, macrosomia, neonatal hypoglycaemia and jaundice
  • Medication use 21% higher — likely the mechanism, not a harm
  • Randomised and observational studies pooled together; treat outcomes cautiously

The statistics, in plain English

The glycaemic differences are statistically significant but clinically small: a mean glucose difference of 0.24 mmol/L would not change management on its own. That the clinical outcomes improved considerably more than the glucose numbers suggests the benefit is mediated by what clinicians did with the extra information. Pooling observational studies with randomised ones tends to inflate apparent benefit, because women offered continuous monitoring differ systematically from those who are not.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

contraceptionlabourpretermmaternal

Tomorrow morning, before your first patient

One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app